The estimated Net Worth of Una S Ryan is at least $479 Thousand dollars as of 13 May 2019. Una Ryan owns over 2,875 units of Cortexyme Inc stock worth over $5,606 and over the last 5 years he sold CRTX stock worth over $0. In addition, he makes $473,254 as Lead Independent Director at Cortexyme Inc.
Sign up
Una Ryan CRTX stock SEC Form 4 insiders trading
Una has made over 1 trades of the Cortexyme Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,875 units of CRTX stock worth $48,875 on 13 May 2019.
The largest trade he's ever made was buying 2,875 units of Cortexyme Inc stock on 13 May 2019 worth over $48,875. On average, Una trades about 719 units every 0 days since 2019. As of 13 May 2019 he still owns at least 2,875 units of Cortexyme Inc stock.
You can see the complete history of Una Ryan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Una Ryan biography
Dr. Una Ryan OBE, Ph.D. serves as Lead Independent Director of the Company. Dr. Ryan has served as a Managing Director at Golden Seeds LLC since 2012, a Partner at Astia Angel since 2012, and a Limited Partner at Breakout Ventures since 2016. She was Chairman of The Bay Area BioEconomy Initiative from 2012 to 2015. Dr. Ryan served as the President and Chief Executive Officer at Waltham Technologies, Inc. from 2008 to 2010. She served as the Chief Executive Officer, President and Chief Operating Officer of AVANT Immunotherapeutics Inc. from 1998 to 2008 (which then became known as Celldex, Inc). She also served as the President and Chief Executive Officer of Diagnostics for All, or DFA from 2009 to 2012 and as Director of Health Sciences at Monsanto Corporation from 1989 to 1993. Dr. Ryan serves on the board of directors of the following private companies: RenovoRx, Elemental Machines and Nativis, Inc. She also serves on the board of directors of the following non-profit entities: Cambridge in America, the University of Bristol Foundation and the San Francisco Art Institute. Dr. Ryan served as a director on the board of directors for AVANT Immunotherapeutics, Inc, AMRIGlobal, Inc, BayBio, MassBio, BIO, or Biotechnology Innovation Organization, New England Healthcare Institute, Board of Associates of the Whitehead Institute and Strategy & Policy Council of the MIT Center for Biomedical Innovation. Dr. Ryan holds a B.S. in Zoology, Microbiology, Chemistry from Bristol University and a Ph.D. in Cellular and Molecular Biology from Cambridge University. Dr. Ryan was awarded the Order of the British Empire for services to biotechnology. Ryan is qualified to serve as a director because of her extensive experience in the biotechnology industry and her service on a number of boards of companies, which provides an important perspective on operations and corporate governance matters.
What is the salary of Una Ryan?
As the Lead Independent Director of Cortexyme Inc, the total compensation of Una Ryan at Cortexyme Inc is $473,254. There are 10 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of $1,100,170.
How old is Una Ryan?
Una Ryan is 78, he's been the Lead Independent Director of Cortexyme Inc since 2019. There are no older and 18 younger executives at Cortexyme Inc.
What's Una Ryan's mailing address?
Una's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Cortexyme Inc
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
What does Cortexyme Inc do?
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
What does Cortexyme Inc's logo look like?
Complete history of Una Ryan stock trades at Cortexyme Inc
Cortexyme Inc executives and stock owners
Cortexyme Inc executives and other stock owners filed with the SEC include:
-
Michael Detke,
Chief Medical Officer -
Margaret Mcloughlin,
Independent Director -
Casey C. Lynch,
Co-Founder, Chairman, Pres & CEO -
Christopher Senner,
Independent Director -
Dr. Michael J. Detke M.D., Ph.D.,
Chief Medical Officer -
Dr. Leslie J. Holsinger Ph.D.,
Exec. VP of R&D -
Casey Lynch,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Christopher P. Lowe M.B.A.,
COO, CFO & Treasurer -
Caryn Gordon McDowell,
Chief Legal & Admin. Officer and Corp. Sec. -
Stephen Dominy,
Co-Founder, Chief Scientific Officer, Director -
Una Ryan,
Lead Independent Director -
Kevin Young,
Independent Director -
Christopher Lowe,
Chief Financial Officer, Treasurer -
David Lamond,
Independent Director -
Dr. Stephen S. Dominy,
Co-Founder, Chief Scientific Officer & Director -
Caryn McDowell,
Chief Legal and Administrative Officer, Corporate Secretary -
Leslie Holsinger,
Executive Vice President - Preclinical Development -
Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D.,
Chief Medical Officer -
Brendan Hannah M.B.A.,
Chief Bus. Officer -
Dr. Dirk Thye M.D.,
CEO & Director -
Mary Ellen Sillivos,
VP of HR -
Stacy Roughan,
VP of Corp. Communications & IR -
Ted Monohon,
VP of Fin. & Chief Accounting Officer -
Ansbert Gadicke,
-
James B Tananbaum,
Director -
Christopher T Phd Walsh,
Director -
Richard W Dugan,
Director -
M Cory Zwerling,
Director -
Luke Evnin,
-
Michael Steinmetz,
-
Kurt Wheeler,
-
Nicholas Galakatos,
Director -
Bioventures Ii Qp Lpmpm Bio...,
-
Dana Charles Hilt,
SVP of Clinical Develop. & CMO -
Philip S Low,
Director -
Marwan Sabbagh,
Director -
Brendan Hannah,
Chief Business Officer -
Dirk Thye,
Chief Executive Officer -
Karen L. Smith,
Chief Medical Officer -
Laura Shawver,
Director -
Michael Thomas Heffernan,
Director -
Andreas Maetzel,
VP, Clinical and Regulatory -
Robert Stephan,
Director -
Alan Roberts,
VP, Scientific Affairs -
Craig A Collard,
President and CEO -
James A Harper,
Director -
Ira Duarte,
Principal Accounting Officer -
Alastair Stuart Mcewan,
Director -
Farmaceutici Sp A Chiesi,
10% owner -
Christopher George Codeanne,
Director -
Joshua B Franklin,
VP, Sales and Marketing -
Marco Vecchia,
Director -
Kenneth Mc Bean,
President -
Anton Giorgio Failla,
Director -
Michael David Enright,
Director -
Ventures, Inc.Takeda Pharma...,
-
Paul D Rubin,
President and CEO -
Inc Pfizer Ventures (Us) Ll...,
-
Pierre Lamond Christine Lamond,
-
Walter Newman,
Chief Scientific Officer/VP RD -
Howland Shaw Warren,
Director -
Frederick Finnegan,
VP of Sales and Marketing -
Robert H Zeiger,
Director -
Technology Ventures Vii Lp ...,
-
Christopher Mirabelli,
Director -
Ventures Vi Lphealthcare Pa...,
-
Jean George,
Director -
Ventures, Inc. Med Immune,
10% owner -
Bioventures Iii Qp Lpmpm Bi...,
-
Jean Advanced Technology Ve...,
-
Frank E Thomas,
CFO, VP Finance and Treasurer -
& Johnson Johnson & Johnson...,
-
Alessandro Chiesi,
Director -
Vincent T. Morgus,
EVP, Finance and CFO -
Brian Dickson,
Chief Medical Officer -
Steven Michael Lutz,
Executive Vice President -
David Price,
Chief Financial Officer -
Bio Pharma Holdings, Ltd. C...,
10% owner -
Scott B Townsend,
VP OF LEGAL AFFAIRS AND SEC. -
Jeffrey E Young,
VP FINANCE, CAO AND TREASURER -
Trevor Phillips,
COO, VP of Operations and Sec. -
George Arthur Esgro,
Vice President Sales -
Chenyqua Michele Baldwin,
Vice President Finance -
Thomas Patrick Kelly,
CFO & SVP Finance & Corp. Dev, -
Capital Group, Llc Boeding ...,
-
Kristen Gafric,
SVP, Legal & Administration -
Inc Pfizer Strategic Invest...,
-
Ted Monohon,
Chief Accounting Officer & VP -
June Bray,
Director